{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:42:25Z","timestamp":1791859345724,"version":"4.3.4"},"reference-count":77,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2019,8,1]]},"DOI":"10.1001\/jamadermatol.2019.0696","type":"journal-article","created":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T15:33:41Z","timestamp":1559144021000},"page":"929","source":"Crossref","is-referenced-by-count":118,"title":["Treatment Outcomes of Topical Calcineurin Inhibitor Therapy for Patients With Vitiligo"],"prefix":"10.1001","volume":"155","author":[{"given":"Ji Hae","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Dermatology, St Vincent\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyuck Sun","family":"Kwon","sequence":"additional","affiliation":[{"name":"Department of Dermatology, St Vincent\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han Mi","family":"Jung","sequence":"additional","affiliation":[{"name":"Department of Dermatology, St Vincent\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunyong","family":"Lee","sequence":"additional","affiliation":[{"name":"Clinical Research Coordinating Center, Catholic Medical Center, The Catholic University of Korea, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyong Moon","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Dermatology, St Vincent\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeon Woo","family":"Yim","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Min","family":"Bae","sequence":"additional","affiliation":[{"name":"Department of Dermatology, St Vincent\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"doi190023r1","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.jaad.2010.11.061","article-title":"Vitiligo: a comprehensive overview\u2014part I: introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up.","volume":"65","author":"Alikhan","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"doi190023r2","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/bjd.2018.178.issue-1","article-title":"Factors affecting quality of life in patients with vitiligo: a nationwide study.","volume":"178","author":"Bae","year":"2018","journal-title":"Br J Dermatol"},{"issue":"1","key":"doi190023r3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/bjd.2012.168.issue-1","article-title":"Guidelines for the management of vitiligo: the European Dermatology Forum consensus.","volume":"168","author":"Taieb","year":"2013","journal-title":"Br J Dermatol"},{"issue":"5","key":"doi190023r4","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1111\/1346-8138.12099","article-title":"Guidelines for the diagnosis and treatment of vitiligo in Japan.","volume":"40","author":"Oiso","year":"2013","journal-title":"J Dermatol"},{"issue":"5","key":"doi190023r5","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.jaad.2015.11.044","article-title":"The efficacy of 308-nm excimer laser\/light (EL) and topical agent combination therapy versus EL monotherapy for vitiligo: a systematic review and meta-analysis of randomized controlled trials (RCTs).","volume":"74","author":"Bae","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"doi190023r6","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1111\/j.1468-3083.2011.04002.x","article-title":"Treatment of vitiligo with narrowband-UVB (TL01) combined with tacrolimus ointment (0.1%) vs placebo ointment, a randomized right\/left double-blind comparative study.","volume":"25","author":"Nordal","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"doi190023r7","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1001\/archderm.139.5.581","article-title":"A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo.","volume":"139","author":"Lepe","year":"2003","journal-title":"Arch Dermatol"},{"issue":"1","key":"doi190023r8","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jaad.2003.12.031","article-title":"Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines.","volume":"51","author":"Grimes","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"doi190023r9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement.","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"issue":"3","key":"doi190023r10","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials.","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"issue":"7414","key":"doi190023r11","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses.","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"8","key":"doi190023r12","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.jclinepi.2014.03.003","article-title":"In meta-analyses of proportion studies, funnel plots were found to be an inaccurate method of assessing publication bias.","volume":"67","author":"Hunter","year":"2014","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"doi190023r13","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/bjd.2009.161.issue-3","article-title":"Analysis of interleukin-10 levels in lesions of vitiligo following treatment with topical tacrolimus.","volume":"161","author":"Taher","year":"2009","journal-title":"Br J Dermatol"},{"issue":"3","key":"doi190023r14","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/j.1365-2133.2005.06739.x","article-title":"FK506 promotes melanocyte and melanoblast growth and creates a favourable milieu for cell migration via keratinocytes: possible mechanisms of how tacrolimus ointment induces repigmentation in patients with vitiligo.","volume":"153","author":"Lan","year":"2005","journal-title":"Br J Dermatol"},{"issue":"5","key":"doi190023r15","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1111\/bjd.2006.155.issue-5","article-title":"FK506 increases pigmentation and migration of human melanocytes.","volume":"155","author":"Kang","year":"2006","journal-title":"Br J Dermatol"},{"issue":"3","key":"doi190023r16","first-page":"490","article-title":"FK506 (tacrolimus) and endothelin combined treatment induces mobility of melanoblasts: new insights into follicular vitiligo repigmentation induced by topical tacrolimus on sun-exposed skin.","volume":"164","author":"Lan","year":"2011","journal-title":"Br J Dermatol"},{"issue":"5","key":"doi190023r17","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/jdv.2013.27.issue-5","article-title":"Endothelin-1 enhances the proliferation of normal human melanocytes in a paradoxical manner from the TNF-a\u2013inhibited condition, but tacrolimus promotes exclusively the cellular migration without proliferation: a proposed action mechanism for combination therapy of phototherapy and topical tacrolimus in vitiligo treatment.","volume":"27","author":"Lee","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"doi190023r18","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/pcmr.2016.29.issue-4","article-title":"FK506 positively regulates the migratory potential of melanocyte-derived cells by enhancing syndecan-2 expression.","volume":"29","author":"Jung","year":"2016","journal-title":"Pigment Cell Melanoma Res"},{"issue":"3","key":"doi190023r19","doi-asserted-by":"publisher","first-page":"287","DOI":"10.4196\/kjpp.2017.21.3.287","article-title":"Pimecrolimus increases the melanogenesis and migration of melanocytes in vitro.","volume":"21","author":"Xu","year":"2017","journal-title":"Korean J Physiol Pharmacol"},{"issue":"3","key":"doi190023r20","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/ced.2016.41.issue-3","article-title":"A combination of excimer laser treatment and topical tacrolimus is more effective in treating vitiligo than either therapy alone for the initial 6 months, but not thereafter.","volume":"41","author":"Park","year":"2016","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"doi190023r21","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/pcmr.2016.29.issue-2","article-title":"FK506 regulates pigmentation by maturing the melanosome and facilitating their transfer to keratinocytes.","volume":"29","author":"Jung","year":"2016","journal-title":"Pigment Cell Melanoma Res"},{"issue":"2","key":"doi190023r22","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00403-009-0973-3","article-title":"Time-kinetic study of repigmentation in vitiligo patients by tacrolimus or pimecrolimus.","volume":"302","author":"Lubaki","year":"2010","journal-title":"Arch Dermatol Res"},{"issue":"1","key":"doi190023r23","first-page":"344","article-title":"The efficacy and safety of topical tacrolimus in patients with vitiligo [abstract].","volume":"119","author":"Soriano","year":"2002","journal-title":"J Invest Dermatol"},{"issue":"2","key":"doi190023r24","first-page":"158","article-title":"Tacrolimus ointment 0.1% produces repigmentation in patients with vitiligo: results of a prospective patient series.","volume":"71","author":"Tanghetti","year":"2003","journal-title":"Cutis"},{"issue":"6","key":"doi190023r25","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/ced.2004.29.issue-6","article-title":"Topical tacrolimus for treatment of childhood vitiligo in Asians.","volume":"29","author":"Kanwar","year":"2004","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"doi190023r26","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0001-7310(05)73058-1","article-title":"Vitiligo: treatment of 12 cases with topical tacrolimus [Spanish].","volume":"96","author":"Almeida","year":"2005","journal-title":"Actas Dermosifiliogr"},{"issue":"6","key":"doi190023r27","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1080\/09546630601028711","article-title":"Topical pimecrolimus: a new horizon for vitiligo treatment?","volume":"17","author":"Sendur","year":"2006","journal-title":"J Dermatolog Treat"},{"key":"doi190023r28","first-page":"65","article-title":"Topical pimecrolimus in vitiligo\u2014a preliminary study [abstract].","volume":"157","author":"Kanwar","year":"2007","journal-title":"Br J Dermatol"},{"issue":"3","key":"doi190023r29","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1159\/000099592","article-title":"Pimecrolimus cream in repigmentation of vitiligo.","volume":"214","author":"Seirafi","year":"2007","journal-title":"Dermatology"},{"key":"doi190023r30","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1111\/dth.2008.21.issue-s1","article-title":"Targeted and combination treatments for vitiligo. Comparative evaluation of different current modalities in 458 subjects.","volume":"21","author":"Lotti","year":"2008","journal-title":"Dermatol Ther"},{"issue":"11","key":"doi190023r31","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1111\/jdv.2009.23.issue-11","article-title":"Pimecrolimus: a new choice in the treatment of vitiligo?","volume":"23","author":"Eryilmaz","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"doi190023r32","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/pde.2009.26.issue-3","article-title":"The efficacy of pimecrolimus 1% cream combined with microdermabrasion in the treatment of nonsegmental childhood vitiligo: a randomized placebo-controlled study.","volume":"26","author":"Farajzadeh","year":"2009","journal-title":"Pediatr Dermatol"},{"issue":"8","key":"doi190023r33","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1111\/jdv.2009.23.issue-8","article-title":"Response of vitiligo to once- vs. twice-daily topical tacrolimus: a controlled prospective, randomized, observer-blinded trial.","volume":"23","author":"Radakovic","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"doi190023r34","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/ijd.2009.48.issue-1","article-title":"Efficacy and safety of tarcrolimus cream 0.1% in the treatment of vitiligo.","volume":"48","author":"Xu","year":"2009","journal-title":"Int J Dermatol"},{"issue":"3","key":"doi190023r35","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3109\/09546630903266761","article-title":"Mometasone cream versus pimecrolimus cream for the treatment of childhood localized vitiligo.","volume":"21","author":"K\u00f6se","year":"2010","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"doi190023r36","first-page":"127","article-title":"Combination of topical tacrolimus ointment and NB-UVB for vitiligo on the face and neck.","volume":"39","author":"Suo","year":"2010","journal-title":"J Clin Dermatol"},{"issue":"11","key":"doi190023r37","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1111\/jde.2011.38.issue-11","article-title":"Clinical efficacy and safety of tacrolimus ointment in patients with vitiligo.","volume":"38","author":"Juan","year":"2011","journal-title":"J Dermatol"},{"issue":"6","key":"doi190023r38","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/jde.2011.38.issue-6","article-title":"Effectiveness of 0.1% topical tacrolimus in adult and children patients with vitiligo.","volume":"38","author":"Udompataikul","year":"2011","journal-title":"J Dermatol"},{"issue":"1","key":"doi190023r39","doi-asserted-by":"publisher","first-page":"68","DOI":"10.4103\/0378-6323.90949","article-title":"Segmental vitiligo: a randomized controlled trial to evaluate efficacy and safety of 0.1% tacrolimus ointment vs 0.05% fluticasone propionate cream.","volume":"78","author":"Kathuria","year":"2012","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"11","key":"doi190023r40","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1111\/jde.2013.40.issue-11","article-title":"Long-term efficacy and safety of tacrolimus ointment in the treatment of vitiligo.","volume":"40","author":"Du","year":"2013","journal-title":"J Dermatol"},{"issue":"97","key":"doi190023r41","first-page":"238","article-title":"Efficacy of combination therapy of pimecrolimus 1% cream and mometasone cream with either agent alone in the treatment of childhood vitiligo.","volume":"23","author":"Farajzadeh","year":"2013","journal-title":"J Mazand Univ Med Sci"},{"issue":"2","key":"doi190023r42","first-page":"123","article-title":"Comparison of topical 0.03% tacrolimus with 0.05% clobetasol in treatment of vitiligo.","volume":"26","author":"Rafiq","year":"2016","journal-title":"J Pak Assoc Dermatol"},{"issue":"4","key":"doi190023r43","first-page":"620","article-title":"Effectiveness of topical corticosteroid, topical calcineurin inhibitors and combination of them in the treatment of vitiligo.","volume":"25","author":"Roy","year":"2016","journal-title":"Mymensingh Med J"},{"issue":"3","key":"doi190023r44","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1111\/bjd.2011.165.issue-3","article-title":"A double-blind, randomized, placebo-controlled trial of topical tacrolimus 0.1% vs. clobetasol propionate 0.05% in childhood vitiligo.","volume":"165","author":"Ho","year":"2011","journal-title":"Br J Dermatol"},{"issue":"2","key":"doi190023r45","first-page":"71","article-title":"Vitiligo affecting face: treatment with pimecrolimus cream 1%: pilot study.","volume":"48","author":"Rodr\u00edguez","year":"2004","journal-title":"Dermatol Rev Mex"},{"issue":"5","key":"doi190023r46","doi-asserted-by":"publisher","first-page":"474","DOI":"10.2340\/00015555-0464","article-title":"Occlusive treatment enhances efficacy of tacrolimus 0.1% ointment in adult patients with vitiligo: results of a placebo-controlled 12-month prospective study.","volume":"88","author":"Hartmann","year":"2008","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"doi190023r47","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1684\/ejd.2009.0779","article-title":"An open randomized study to compare narrow band UVB, topical pimecrolimus and topical tacrolimus in the treatment of vitiligo.","volume":"19","author":"Stinco","year":"2009","journal-title":"Eur J Dermatol"},{"issue":"2","key":"doi190023r48","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/jde.2010.37.issue-2","article-title":"Efficacy and safety of topical tacrolimus for the treatment of face and neck vitiligo.","volume":"37","author":"Lo","year":"2010","journal-title":"J Dermatol"},{"issue":"2","key":"doi190023r49","first-page":"115","article-title":"Comparison of treatment with tacrolimus 0.03% and superoxide dismutase and catalase in vitiligo.","volume":"24","author":"Paracha","year":"2010","journal-title":"J Postgrad Med Inst"},{"issue":"1","key":"doi190023r50","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1590\/S0365-05962011000100034","article-title":"Tacrolimus 0,1% ointment in the treatment of vitiligo: a series of cases.","volume":"86","author":"Tamler","year":"2011","journal-title":"An Bras Dermatol"},{"issue":"6","key":"doi190023r51","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1007\/s10103-012-1250-9","article-title":"A comparative study on efficacy of 308nm-excimer laser vs. tacrolimus in the treatment of progressive vitiligo on face or neck [abstract].","volume":"28","author":"Wu","year":"2013","journal-title":"Lasers Med Sci"},{"issue":"1","key":"doi190023r52","first-page":"123","article-title":"Vitiligo, NB-UVB and tacrolimus: our experience in Naples.","volume":"149","author":"Baldo","year":"2014","journal-title":"G Ital Dermatol Venereol"},{"issue":"4","key":"doi190023r53","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.dsi.2016.05.005","article-title":"Comparison of the efficacy and safety of 0.1% tacrolimus ointment and 0.1% mometasone furoate cream for adult vitiligo: a single-blinded pilot study.","volume":"34","author":"Silpa-Archa","year":"2016","journal-title":"Dermatologica Sinica"},{"issue":"1","key":"doi190023r54","doi-asserted-by":"publisher","first-page":"29","DOI":"10.4103\/2231-4040.197388","article-title":"Effectiveness and safety of topical tacrolimus in treatment of vitiligo.","volume":"8","author":"Rokni","year":"2017","journal-title":"J Adv Pharm Technol Res"},{"issue":"9","key":"doi190023r55","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1001\/archderm.140.9.1065","article-title":"Topical tacrolimus and the 308-nm excimer laser: a synergistic combination for the treatment of vitiligo.","volume":"140","author":"Passeron","year":"2004","journal-title":"Arch Dermatol"},{"issue":"7","key":"doi190023r56","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1111\/jdv.2007.21.issue-7","article-title":"Narrow-band UVB phototherapy combined with tacrolimus ointment in vitiligo: a review of 110 patients.","volume":"21","author":"Fai","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"doi190023r57","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/pde.2009.26.issue-3","article-title":"Combination of 308-nm excimer laser with topical pimecrolimus for the treatment of childhood vitiligo.","volume":"26","author":"Hui-Lan","year":"2009","journal-title":"Pediatr Dermatol"},{"issue":"8","key":"doi190023r58","doi-asserted-by":"publisher","first-page":"e1029","DOI":"10.1111\/ced.2009.34.issue-8","article-title":"Topical tacrolimus may enhance repigmentation with targeted narrowband ultraviolet B to treat vitiligo: a randomized, controlled study.","volume":"34","author":"Klahan","year":"2009","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"doi190023r59","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/ppp.2010.26.issue-5","article-title":"Does topical tacrolimus ointment enhance the efficacy of narrowband ultraviolet B therapy in vitiligo? a left-right comparison study.","volume":"26","author":"Majid","year":"2010","journal-title":"Photodermatol Photoimmunol Photomed"},{"issue":"4","key":"doi190023r60","doi-asserted-by":"publisher","first-page":"525","DOI":"10.4103\/0378-6323.113091","article-title":"Efficacy and tolerability of combined treatment with NB-UVB and topical tacrolimus versus NB-UVB alone in patients with vitiligo vulgaris: a randomized intra-individual open comparative trial.","volume":"79","author":"Satyanarayan","year":"2013","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"4","key":"doi190023r61","first-page":"327","article-title":"Efficacy of 0.1% topical tacrolimus with narrow band ultraviolet B phototherapy versus narrow band ultraviolet B phototherapy in vitiligo.","volume":"24","author":"Bilal","year":"2014","journal-title":"J Pak Assoc Dermatol"},{"issue":"6","key":"doi190023r62","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1111\/pde.2016.33.issue-6","article-title":"Treatment of childhood vitiligo using tacrolimus ointment with narrowband ultraviolet B phototherapy.","volume":"33","author":"Dayal","year":"2016","journal-title":"Pediatr Dermatol"},{"issue":"1","key":"doi190023r63","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1080\/09546630802155057","article-title":"The efficacy of pimecrolimus 1% cream plus narrow-band ultraviolet B in the treatment of vitiligo: a double-blind, placebo-controlled clinical trial.","volume":"20","author":"Esfandiarpour","year":"2009","journal-title":"J Dermatolog Treat"},{"issue":"11","key":"doi190023r64","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/ddg.2006.4.issue-11","article-title":"Efficacy and safety of pimecrolimus cream 1% in adult patients with vitiligo: results of a randomized, double-blind, vehicle-controlled study.","volume":"4","author":"Dawid","year":"2006","journal-title":"J Dtsch Dermatol Ges"},{"issue":"3","key":"doi190023r65","first-page":"232","article-title":"Efficacy of tacrolimus plus narrowband ultraviolet B phototherapy versus narrowband ultraviolet B phototherapy alone in the treatment of vitiligo.","volume":"27","author":"Ullah","year":"2017","journal-title":"J Pak Assoc Dermatol"},{"issue":"4","key":"doi190023r66","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1038\/jid.2014.527","article-title":"Maintenance therapy of adult vitiligo with 0.1% tacrolimus ointment: a randomized, double blind, placebo-controlled study.","volume":"135","author":"Cavali\u00e9","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"5","key":"doi190023r67","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1046\/j.1523-1747.2002.01709.x","article-title":"Localization of calcineurin\/NFAT in human skin and psoriasis and inhibition of calcineurin\/NFAT activation in human keratinocytes by cyclosporin A.","volume":"118","author":"Al-Daraji","year":"2002","journal-title":"J Invest Dermatol"},{"issue":"1","key":"doi190023r68","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1046\/j.0022-202X.2003.22110.x","article-title":"Variations of hair follicle size and distribution in different body sites.","volume":"122","author":"Otberg","year":"2004","journal-title":"J Invest Dermatol"},{"issue":"9","key":"doi190023r69","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1111\/jdv.2012.26.issue-9","article-title":"Acral lesions of vitiligo: why are they resistant to photochemotherapy?","volume":"26","author":"Esmat","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"doi190023r70","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1001\/jamadermatol.2017.0002","article-title":"Phototherapy for vitiligo: a systematic review and meta-analysis.","volume":"153","author":"Bae","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"4","key":"doi190023r71","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.jaad.2017.05.043","article-title":"Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure.","volume":"77","author":"Liu","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"doi190023r72","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.jaad.2018.02.023","article-title":"Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: a 32-week open-label extension study with optional narrow-band ultraviolet B.","volume":"78","author":"Joshipura","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"doi190023r73","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1001\/archderm.142.2.252","article-title":"Lack of efficacy of tacrolimus in the treatment of vitiligo in the absence of UV-B exposure.","volume":"142","author":"Ostovari","year":"2006","journal-title":"Arch Dermatol"},{"issue":"1","key":"doi190023r74","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1600-0625.2007.00617.x","article-title":"Topical tacrolimus in combination with simulated solar radiation does not enhance photocarcinogenesis in hairless mice.","volume":"17","author":"Lerche","year":"2008","journal-title":"Exp Dermatol"},{"issue":"4","key":"doi190023r75","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1159\/000088505","article-title":"Topical calcineurin inhibitors decrease the production of UVB-induced thymine dimers from hairless mouse epidermis.","volume":"211","author":"Tran","year":"2005","journal-title":"Dermatology"},{"issue":"6","key":"doi190023r76","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1111\/jde.2011.38.issue-6","article-title":"Inhibitory potency of tacrolimus ointment on skin tumor induction in a mouse model of an initiation-promotion skin tumor.","volume":"38","author":"Mitamura","year":"2011","journal-title":"J Dermatol"},{"issue":"2","key":"doi190023r77","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/j.1365-2133.2010.10030.x","article-title":"Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials.","volume":"164","author":"Schmitt","year":"2011","journal-title":"Br J Dermatol"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/article-pdf\/155\/8\/929\/17752750\/jamadermatology_lee_2019_oi_190023.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T20:50:54Z","timestamp":1721335854000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2734015"}},"subtitle":["A Systematic Review and Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2019,8,1]]},"references-count":77,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2019.0696","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8,1]]}}}